Johnson & Johnson reports lower mortality rates with Impella heart pumps

What happened

Johnson & Johnson reported three analyses of 1,379 patients who received Impella heart-pump support during high-risk heart procedures. The data came from hospitals in the United States and Europe and showed lower death rates than those reported in the CHIP-BCIS3 study. The comparisons were observational, not randomized.

Global impact / market context

The results may shape how doctors and investors view Impella, but the data do not prove the pump caused the lower death rates. The findings are therefore not a direct test of whether the device improves survival.

What to watch

1. Check the full analyses when they are presented at TCT 2026; details may clarify how the patient groups were compared.
2. Check whether later reports give more detail on in-hospital, 30-day, and 90-day deaths; these periods show how the reported results vary over time.
3. Check for the PROTECT IV trial result, which is anticipated in 2027; a trial result could add evidence beyond observational data.

Affected assets

• Impella heart pump
• JNJ

Evidence

• Infoway News — Johnson & Johnson reports lower mortality rates with Impella heart pumps 2026-11-01T15:14:29+00:00
• Infoway News — Johnson & Johnson (JNJ) Reports Positive Real-World Impella HRPCI Outcomes vs CHIP-BCIS3 2026-11-01T13:00:00+00:00
• Infoway News — Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results 2026-11-01T13:00:00+00:00
• Incident timeline — Johnson & Johnson reports lower mortality rates with Impella heart pumps
• Incident timeline — Johnson & Johnson (JNJ) Reports Positive Real-World Impella HRPCI Outcomes vs CHIP-BCIS3
• Incident timeline — Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results